Myriad Genetics Inc reports results for the quarter ended December 31 - Earnings Summary

Myriad Genetics

24/02/2025 22:41

* Myriad Genetics Inc  MYGN.OQ  reported quarterly adjusted
earnings of 3 cents​​ per share for the quarter ended December
31, lower than the same quarter last year, when the company
reported EPS of 4 cents.  The mean expectation of
seventeen analysts for the quarter was for earnings of 3 cents
per share. Wall Street expected results to range from 2 cents
to 5 cents per share.
    * Revenue rose 7.1% to $210.60 million from a year ago;
analysts
expected $211.62 million. 
    * Myriad Genetics Inc's reported EPS for the quarter was a
loss
of 47 cents​.
    * The company reported a quarterly loss of $42.5 million.
    * Myriad Genetics Inc shares had risen by 3.4% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 13% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 6
"hold" and 4 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Myriad Genetics
Inc is $18.00 
This summary was machine generated from LSEG data February 24 at
10:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      0.03           0.03           Met
 Sep. 30 2024      0.02           0.06           Beat
 Jun. 30 2024      -0.01          0.05           Beat
 Mar. 31 2024      -0.10          -0.01          Beat